CES1 Genotype

One liver enzyme handles an outsized share of the drugs people actually take: methylphenidate for attention deficit hyperactivity disorder, clopidogrel, dabigatran, several blood pressure pills, and oseltamivir. The enzyme is carboxylesterase 1, often shortened to CES1. It performs a chemical step that either switches a drug on or shuts it off.

The gene that builds it varies between people, and a small slice of the population carries a version that barely works. If you are one of them, a drug this enzyme clears can linger, and a drug it activates may arrive more weakly.

What the Enzyme Actually Does

Many drugs are built with a chemical joint that water can pull apart. Sometimes breaking that joint is the whole point: the molecule you swallow is inert, and the split product is the real drug. Just as often the reverse is true, and breaking the joint is how your body disposes of something active.

Carboxylesterase 1 does the cutting. It is made mostly in the liver, where it is the single most abundant drug-handling enzyme and carries out the large majority of this kind of breakdown. Because this step can happen early in a drug's path through the body, small differences in how well the enzyme works can change how much parent drug or active drug reaches your bloodstream.

The One Variant With Real Human Data

Most of what is known clinically comes down to a single change, written on reports as G143E or rs71647871. It swaps one amino acid and leaves the enzyme with a fraction of its normal activity. Reviews of this gene describe it as the only CES1 variant with clear clinical significance so far. Carrying one copy is enough to show up in drug levels. Carrying two, which is very rare, would be expected to matter more.

This is still an emerging pharmacogenetic marker. It is not used on its own the way CYP2C19 is used for clopidogrel or VKORC1 is used for warfarin. Its best use is to explain outlier drug response and to plan closer monitoring when an affected prescription is on the table.

Ancestry changes how much a result tells you. Carrier frequency is best documented in European datasets, where roughly 1 to 4 percent of people carry one copy. Population database figures suggest the variant is less common in East Asian groups and varies across African, Hispanic, and South Asian cohorts, though those estimates rest on thinner evidence than the European numbers. A negative single-variant result is narrower than it sounds: it rules out the checked variant, not every way this enzyme can run slow. Even G143E plus alcohol together explain only a small share of the person-to-person differences in this enzyme's activity.

Stimulants Like Methylphenidate

Methylphenidate is the cleanest example, because this enzyme does nearly all the work of clearing it. In human liver tissue, samples carrying one weak copy break the drug down at roughly half the normal rate, and a Danish pharmacokinetic study found carriers reached substantially higher blood levels after the same dose. That can mean stronger stimulant effects. The direct human evidence is strongest for drug levels; links to specific side effects such as appetite loss, sleep trouble, heart rate, and blood pressure are plausible but thinner. One treatment study found carriers needed lower doses but were no more or less likely to respond overall.

Alcohol pushes in the same direction. Drinking while methylphenidate is on board raises its peak concentration by roughly a third, because the same enzyme diverts part of the drug into a different product instead of clearing it. This is one of the few drug interactions here confirmed in people rather than in a test tube.

Clopidogrel and Dabigatran Pull in Opposite Directions

Clopidogrel has to be activated in the liver to do anything, and most of what you swallow never gets that far, because this enzyme destroys it first. A weaker enzyme wastes less of the dose. In a human study, G143E carriers hydrolyzed about half as much of the drug, ended up with roughly two-thirds more of the active form in their blood, and showed stronger suppression of platelet clumping.

Dabigatran runs the other way. It is given as an inactive precursor, and CES1 helps convert it into the working anticoagulant after earlier steps. In a genetic analysis of the RE-LY dabigatran trial, two common CES1 variants were tied to lower drug levels, and one of them to less bleeding. Those are not G143E. Later cohorts in China reported the opposite direction for the same variants, with higher trough levels and more bleeding, and a 2025 systematic review again pointed to one of those common variants rather than G143E as the main CES1 contributor. So a single-variant result is not a dabigatran dosing answer.

What this means for you: there is no good result and no bad result here. A slow enzyme is a liability with one drug and an advantage with the next, and the direction flips depending on whether the enzyme is the on switch or the off switch. Read your result as information about a chemical step, not as a verdict on your health.

Blood Pressure Pills and Other Prodrugs

Several widely used medications arrive as inert precursors and depend on this same enzyme to become active. Enalapril and ramipril among the blood pressure drugs. Sacubitril, the newer half of the heart failure combination sold as Entresto. Oseltamivir for influenza.

Enalapril becomes enalaprilat before it lowers blood pressure. In a small multi-dose study in healthy volunteers, G143E carriers produced roughly a quarter to a third less enalaprilat and showed no clear drop in systolic blood pressure, while non-carriers fell by about 12 percent. Trandolapril is also handled by this enzyme in laboratory work, but the effect of genotype on it has not been pinned down in people. For ramipril, sacubitril, and oseltamivir, much of the evidence is drug chemistry, liver samples, or drug-level studies rather than outcome trials.

That is enough to make a variant worth noticing. It is not enough to replace checking whether the medication is working.

Why This Result Can Be Misread

• A difficult stretch of DNA: the gene has a nearly identical neighbor on the same chromosome that does not produce a working enzyme, and hybrid arrangements of the two exist. Sequencing can misassign reads in this region, so it is fair to ask whether your lab reports copy number and how it separates the two.
• Panel coverage: a test that checks only G143E does not rule out every rare CES1 change. Full-gene sequencing sees more, but it also finds more variants with no clear drug meaning.
• Variants with no known meaning: sequencing the full gene turns up rare changes nobody has studied. A report listing one of these is not, by itself, a reason to change a prescription.
• Ancestry and base rates: the chance of finding a known variant differs by ancestry and by the database used. A negative result means less when the tested variant was unlikely in you to begin with.
• Genotype is not activity: enzyme capacity also falls with liver disease, shifts with age and sex, and can be blunted by alcohol or other drugs. A normal genotype does not guarantee normal enzyme function on the day you take a pill.
• Tumor-only or unusual blood DNA: this should be a germline result. Tumor sequencing, donor marrow, or some blood cancers can confuse inherited DNA with acquired changes.
• Consumer array results: ancestry chips sometimes report a position in this gene. Those calls are not clinical grade and should be confirmed by sequencing before anyone acts on them.

A Test You Take Once

Your genotype was fixed before you were born and will read the same in ten years. There is nothing to trend. Get it once, keep the report, and give it to whoever writes your prescriptions.

What you do track is the drug's effect. On a stimulant, that means resting heart rate and blood pressure at the start, again a few weeks in, and at least yearly after that. On clopidogrel, it means platelet function testing if your cardiologist uses it. On dabigatran, it means kidney function, which drives clearance far more than genetics does.

What to Do With a Variant

First, make sure the call is real. If it came from an array rather than sequencing, or the report flags thin coverage over the region, confirm it by a second method before anything changes. Then decide what it actually touches, which is only the drugs this enzyme handles.

• Starting a stimulant: begin at the low end and titrate slowly, watching cardiovascular vitals instead of assuming the standard escalation schedule fits you.
• On clopidogrel: order CYP2C19 genotyping alongside this one. CYP2C19 handles the activation step and remains the variant that actually guides therapy, while CES1 destroys much of the drug before activation can happen.
• On dabigatran: kidney function and bleeding history still drive the dose. CES1 genotype is a secondary consideration and is not currently used to pick a dose.
• On enalapril, ramipril, oseltamivir, or sacubitril: do not switch only because of genotype. Check the actual response, such as blood pressure, symptom response, or the clinical marker the drug is meant to change.
• For family: if you carry one copy, each biological child has a 50% chance of carrying it too. Parents and siblings may also carry it, which matters most when one of these prescriptions comes up.

If you are on several affected medications at once, a pharmacist trained in pharmacogenomics is usually the best first stop. A genetic counselor can help if the result came from broad sequencing or if family testing feels hard to sort out, but there is no inherited disease syndrome here. The value is in medication review.